Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
1.
Eur Arch Otorhinolaryngol ; 280(5): 2623-2631, 2023 May.
Article in English | MEDLINE | ID: covidwho-2288355

ABSTRACT

PURPOSE: To screen for oropharyngeal dysphagia (OD) in hospitalized COVID-19 patients. METHODS: A descriptive longitudinal study was conducted on 500 adult patients with confirmed COVID-19 in the age range of 19-65 years who were admitted to the main university isolation hospital (whether admitted in the ward or the intensive care unit). Screening for OD was done using the Arabic version of the Eating Assessment Tool (EAT-10) and the Yale swallow protocol. RESULTS: 45.4% of the admitted and 40.97% of the discharged COVID-19 patients had a positive screen for OD. Several risk factors for OD could be detected. These include older age, longer duration of presenting symptoms of COVID-19, presence of ageusia and anosmia, presence of dysphonia, ICU admission, lower oxygen saturation, higher respiratory rate, presence of OD at admission, longer duration of hospital stay, and use of noninvasive ventilation (NIV) and/or invasive mechanical ventilation (IMV). CONCLUSIONS: Screening for OD in hospitalized COVID-19 patients is a mandatory procedure, whether for admitted or discharged patients.


Subject(s)
COVID-19 , Deglutition Disorders , Adult , Humans , Young Adult , Middle Aged , Aged , COVID-19/complications , Deglutition Disorders/diagnosis , Deglutition Disorders/etiology , Prospective Studies , Longitudinal Studies , Hospitalization
2.
Inflammopharmacology ; 30(6): 1935-1954, 2022 Dec.
Article in English | MEDLINE | ID: covidwho-2014260

ABSTRACT

The pandemic spread of coronavirus (COVID-19) has been reported first at the end of 2019. It continues disturbing various human aspects with multiple pandemic waves showing more fatal novel variants. Now Egypt faces the sixth wave of the pandemic with controlled governmental measures. COVID-19 is an infectious respiratory disease-causing mild to moderate illness that can be progressed into life-threatening complications based on patients- and variant type-related factors. The symptoms vary from dry cough, fever to difficulty in breathing that required urgent hospitalization. Most countries have authorized their national protocols for managing manifested symptoms and thus lowering the rate of patients' hospitalization and boosting the healthcare systems. These protocols are still in use even with the development and approval of several vaccines. These protocols were instructed to aid home isolation, bed rest, dietary supplements, and additionally the administration of antipyretic, steroids, and antiviral drugs. The current review aimed to highlight the administered protocols in the Middle East, namely in Egypt and the Kingdom of Saudi Arabia demonstrating how these protocols have shown potential effectiveness in treating patients and saving many soles.


Subject(s)
COVID-19 Drug Treatment , Humans , Pharmaceutical Preparations , Pandemics/prevention & control , Antiviral Agents/therapeutic use , Middle East/epidemiology
SELECTION OF CITATIONS
SEARCH DETAIL